Say your employer just dropped Wegovy from next year's plan. Now a couple of new programs would let that same employer chip in at the pharmacy counter instead. Lifeline, or loophole? That's where we begin on GLP-1 Daily. It's Monday, November 2. After the employer workarounds, South Korean demand for these drugs keeps climbing, and so do seizures of illegal imports. Then India approves another generic semaglutide pill, this one from Sun Pharma.
Pearl Steinzor, writing for AJMC:
The deal covers both injectable semaglutide, including the higher-dose semaglutide HD, and the once-daily semaglutide pill. Each employer chooses how much to contribute toward treatment, which lowers what employees pay out of pocket while the employer keeps control over its total spending.
That deal is between Novo Nordisk and Andel, a direct-to-employer marketplace, announced in a press release last Wednesday, October 28. The employer drops the drug from its pharmacy benefit but pays part of the worker's cash price. Andel's founder says that contribution can range from about a hundred dollars per fill up to the full cost, set month to month. And it isn't the only one. On Thursday, GoodRx launched what it calls Employer Direct. Employers pick from Wegovy, Wegovy HD, the Wegovy pill, Foundayo and the Zepbound KwikPen, set a contribution, and it's applied automatically when the prescription is filled. Andel, for its part, has worked with Lilly's employer program since May. Why now? AJMC points to the WTW survey we covered last Wednesday: 53 percent of larger employers cover these drugs for weight loss, down from 57. A preliminary Marsh survey projects employer health costs up 8.2 percent in 2027, a full point of it from GLP-1 use. Here's my problem. Spending control is the actual product being sold here. Andel says plainly that its program is not insurance, and participants pay the discounted charges themselves. So the employer's share is a choice that can shrink next year. And I'd want to know, plan by plan, whether spouses and kids are included. The cash prices underneath can move too. The lowest self-pay doses of Wegovy currently run 149 dollars a month for the pill and 199 for the injection, and Novo has said that promotional pricing may change in 2027. If your benefits packet mentions one of these programs, ask three things: how much the company contributes, whether that spending counts toward your deductible, and what happens if the contribution changes mid-year. Then talk it through with your prescriber while open enrollment is still open.
Kim Dong-young, reporting for Aju Press from Seoul:
Lawmakers say price differences have encouraged purchases abroad. The Korea Customs Service intercepted illegally imported obesity drugs 5,030 times in the first eight months of this year, 4.2 times the total for 2025.
On Friday we covered Hanmi's Eppe reaching Korean clinics on October 29, with a starter price around half of Mounjaro's. This piece adds the demand side. Insurance-review data given to a lawmaker show Wegovy and Mounjaro were prescribed about 2.79 million times from January through August, against about 1.22 million in all of 2025. It also fills in something we couldn't give you Friday: how maintenance pricing compares. Aju Press puts Eppe's ten-milligram dose at a supply price of 299,200 won for four weeks, about 20 percent below Wegovy's highest dose and less than half the 675,131 won for Mounjaro's. Those are distributor figures. National insurance doesn't cover obesity treatment, so clinics set what patients actually pay. Meanwhile, a woman in Busan tells the outlet she's happy with the Mounjaro she buys cheaply on trips to Japan, and won't switch to a drug whose effect, as she puts it, hasn't been verified. On results, Hanmi's figure is company-reported from an interim phase 3 analysis: 9.75 percent average weight loss at 40 weeks. The trials behind Eppe, Wegovy and Mounjaro differ in length and design, and none compared all three directly. The line I'd underline came from Hwang Ju-ri of the Korea Biotechnology Industry Organization, who called rebound the biggest side effect to emerge. Aju cites an extension of Wegovy's main trial in which people regained about two-thirds of their lost weight within a year of stopping both the drug and the lifestyle program. When you pay cash, staying on is the real bill. The decision to watch is the one Korea's health minister raised last Tuesday, October 27: whether to bring these drugs into a managed-coverage scheme that controls prices and use.
Abhijeet Singh, writing for ET Pharma:
Indian Pharma major, Sun Pharmaceutical Industries has secured regulatory nod to manufacturer and market its generic semaglutide pill in India. The once-daily drug, therapeutically equivalent to Novo’s Rybelsus, is approved for the treatment for type-2 diabetes and covers three strengths: 3 mg, 7 mg and 14 mg.
ET Pharma posted this on Saturday, October 31, without an exact approval date. The nod comes from India's drug regulator, the CDSCO. Sun will make the pill in Assam, with the active ingredient sourced from a Chinese supplier, and hadn't answered ET Pharma's request for comment. Some background on India's market. Semaglutide lost patent protection there in March, but the pill formulation is covered by a separate patent. Torrent Pharma launched first after the Delhi High Court ruled its version didn't infringe, and ET Pharma says Torrent now holds nearly 90 percent of India's generic semaglutide market. Dr. Reddy's followed with an oral brand, Obeda, at 99 to 225 rupees per tablet depending on strength. That's the same Dr. Reddy's we've been tracking. It paused supply of its generic injectable in July over an ingredient quality problem, and has said it is aiming to relaunch this month, starting in Canada, if validation holds up. This report doesn't update that timeline. Why it's on a show for U.S. patients: the generic field abroad keeps widening. But this is a diabetes pill cleared by India's regulator. It is not an FDA approval. So a generic semaglutide tablet offered to you by an overseas website is not this story. If you're curious about a pill instead of a shot, raise it with your prescriber, and stick to products approved where you live.
One small favor. If this show has made a benefits letter or a drugmaker's announcement easier to decode, leave a rating or a short review in your podcast app. That's how other patients stumble onto us.
So that's Monday: employers hunting for a cheaper side door, Korean demand outrunning its coverage rules, and one more generic pill in India. None of this is medical advice. Your prescriber knows your chart, and we don't. GLP-1 Daily is part of the Lantern Podcasts lineup, and we'll be back tomorrow, Tuesday.